Therefore, VASH2 may represent a novel target for anti-chemoresistance therapy in the gemcitabine chemotherapy of pancreatic cancer; VASH2 may also be used as a marker to guide the gemcitabine chemotherapy of pancreatic cancer. This evidence concerns the gene VASH2 and pancreatic neoplasm.